$ News

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know

Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely?

Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

Vigil Neuroscience: Down On A Competitor's Failure

Vigil Neuroscience to Present at Upcoming Investor Conferences

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake